Saturday, January 31, 2026

Celltrion’s Eydenzelt: How Strategic Patent Agreements Enable U.S. and European Market Entry in 2026

Celltrion's Eydenzelt secures global distribution via strategic patent agreements, aiming for swift market entry in the U.S. and Europe.

Real Madrid Clinches Kylian Mbappe for a Whopping €150 Million Deal!

Kylian Mbappé's move to Spain's Real Madrid is imminent. BBC, known for its credibility, has confirmed Mbappé's entry.

How Trump’s First Year Shapes Korea’s New Foreign Policy Strategy in 2026

Trump's second term emphasizes hardline policies, urging South Korea to adapt its strategies amid a shifting U.S. focus on domestic stability.

Tag: biopharmaceuticals

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Unlocking Opportunities: 2025 Bio GMP Training Program Launches at Daejeon University

Daejeon University launched the 2025 Winter BioRG Training Program for biopharmaceuticals, featuring industry experts and hands-on sessions.

Samsung Biologics Unveils Three-Pillar Growth Strategy: How Capacity, Portfolio, and Global Expansion Shape 2026

Samsung Biologics outlines a growth strategy focused on production, portfolio, and global expansion to enhance its CDMO position.

2026: South Korea’s Advanced Regenerative Medicine R&D Investment Expands – What You Need to Know!

The Ministry of Health and Welfare aims to boost investments in advanced regenerative medicine R&D and improve research infrastructure in South Korea.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.